Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Expenses (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Accumulated Expenses for 7 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 154.2% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, up 154.2% year-over-year, with the annual reading at $9.1 million for FY2025, 154.2% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.1 million at Fulcrum Therapeutics, up from $2.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $10.3 million in Q3 2021, with the low at $1.2 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $5.1 million, with a median of $4.3 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses skyrocketed 502.34% in 2022, then tumbled 72.64% in 2025.
  • Over 5 years, Accumulated Expenses stood at $9.2 million in 2021, then plummeted by 49.08% to $4.7 million in 2022, then surged by 85.66% to $8.7 million in 2023, then crashed by 59.19% to $3.6 million in 2024, then skyrocketed by 154.2% to $9.1 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $9.1 million, $2.8 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.